Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $36.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target lifted by JPMorgan Chase & Co. from $32.00 to $36.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also issued reports on the stock. Piper Sandler reaffirmed an overweight rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Oppenheimer reaffirmed a market perform rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Finally, The Goldman Sachs Group decreased their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of Moderate Buy and a consensus price target of $39.33.

Day One Biopharmaceuticals Trading Down 8.7 %

Shares of NASDAQ:DAWN opened at $15.19 on Monday. The firm has a 50 day moving average of $15.28 and a 200-day moving average of $13.79. The stock has a market capitalization of $1.33 billion, a PE ratio of -6.38 and a beta of -1.48. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, research analysts predict that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the sale, the general counsel now directly owns 16,585 shares in the company, valued at $252,921.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the transaction, the general counsel now directly owns 16,585 shares in the company, valued at $252,921.25. The disclosure for this sale can be found here. Insiders sold a total of 55,781 shares of company stock worth $883,160 over the last three months. 8.40% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Day One Biopharmaceuticals by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after acquiring an additional 346,090 shares during the period. Franklin Resources Inc. lifted its stake in Day One Biopharmaceuticals by 4.2% during the 4th quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock valued at $61,857,000 after acquiring an additional 169,463 shares during the period. Braidwell LP lifted its stake in Day One Biopharmaceuticals by 13.5% during the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares during the period. Goldman Sachs Group Inc. lifted its stake in Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the period. Finally, Polar Capital Holdings Plc lifted its stake in Day One Biopharmaceuticals by 9.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,935,000 shares of the company’s stock valued at $23,742,000 after acquiring an additional 160,385 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.